Yury V. Popov

Associate Professor

Beth Israel Deaconess Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yury V. Popov is an Associate Professor at Beth Israel Deaconess Medical Center in the United States. His research focuses on metabolic dysfunctions and liver diseases, including obesity-related liver conditions and the molecular mechanisms of liver fibrosis and cancer. Recent publications include studies on the metabolomic aspects of liver pathologies and innovative therapeutic approaches for severe liver diseases.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (10)

Eduard Post

University of Groningen

NETHERLANDS

View details

PINZHU HUANG

Beth Israel Deaconess Medical Center

UNITED STATES

View details

Ioannis Vlachos

Broad Institute

UNITED STATES

View details

Klaas Poelstra

Full Professor

University of Groningen

NETHERLANDS

View details

Bo Li

Assistant Professor

Harvard Medical School

UNITED STATES

View details

Samouil Farhi

Broad Institute

UNITED STATES

View details

Jeff Idle

Adjunct Professor

Western New England University

UNITED STATES

View details

Diren Beyoglu

Associate Director and Associate Professor of Systems Pharmacology and Pharmacogenomics

Long Island University

UNITED STATES

View details

Linus Tsai

Assistant Professor

Beth Israel Deaconess Medical Center

UNITED STATES

View details

Anja Hess

Max Planck Institute for Molecular Genetics

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yury V. Popov

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells

Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease

The Metabolomic Footprint of Liver Fibrosis

Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis.

Increased susceptibility to ischemia causes exacerbated response to microinjuries in the cirrhotic liver

ASK1/ p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.

Metabolic Hijacking of Hexose Metabolism to Ascorbate Synthesis Is the Unifying Biochemical Basis of Murine Liver Fibrosis

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4<sup>-/-</sup> mouse model of PFIC3

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets.

3D analysis of microvasculature in murine liver fibrosis models using synchrotron radiation-based microtomography

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis

Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis

Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis

Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer

Collaborators (10)

Eduard Post

PINZHU HUANG

Ioannis Vlachos

Klaas Poelstra

Bo Li

Samouil Farhi

Jeff Idle

Diren Beyoglu

Linus Tsai

Anja Hess

Make your next move.